Psychedelic firms Definium and Compass poised for key data releases

Investors and analysts are focusing on two psychedelic companies as they approach pivotal milestones.

Definium Therapeutics is set to release Phase 3 Voyage data for its single-dose oral LSD candidate DT120 in generalized anxiety disorder, with the readout expected in the coming days.

Earlier this summer, Definium reported late-stage Emerge trial results in major depressive disorder, showing an 8.1-point placebo-adjusted improvement over six weeks, which analysts said exceeded expectations.

Jefferies analysts note that the upcoming anxiety data could lift Definium’s share price by 25-50 percent and expressed 70-75 percent confidence that a single dose can safely deliver a rapid, robust and durable benefit through week 12.